Johnson & Johnson's July 27, 2026 Form 8-K commits $5.5 billion to resolve remaining ovarian talc claims, with the first payment no more than $3 billion in 2027 and nothing further due before 2028. The deal does not close unless at least 95 percent of the remaining claims participate.
On July 27, 2026, Johnson & Johnson filed a Form 8-K. Erik Haas, Worldwide Vice President of Litigation, put $5.5 billion on the table. Ninety-five percent of the remaining ovarian talc claims have to take it, or the deal does not close. That is the lock. The number is not a payment. It is a participation test written into a securities filing.
The 8-K is specific about the money path. "The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028." Per-claim, not a lump fund. First check capped at $3 billion. Nothing else due before 2028. The condition sits in the same paragraph: express participation of at least 95 percent of the remaining claims.
Exhibit 99.1 sharpens the test to the firms. It requires "the participation of lead plaintiff firms in all ovarian talc litigation pending in state and federal court, representing at least 95% of the remaining claims," across roughly 76,000 remaining ovarian talc claims. Haas called the show-cause posture that preceded the filing "a watershed moment," saying plaintiffs "effectively conceded their inability to prove specific causation by withdrawing their experts on the topic in two bellwether cases." Those are the company's words in a press release attached to an 8-K, not findings by any court.
Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.
The pressure point that produced the number is still live. Magistrate Judge Rukhsanah L. Singh, in MDL 2738 before Judge Michael A. Shipp in Newark, had ordered ovarian talc plaintiffs to show cause why remaining claims should not be dismissed for inability to prove specific causation. Sentinel covered that inventory math in Sentinel's earlier file on the federal talc docket: 68,435 pending actions, a third of the federal MDL docket. The 8-K is the price Haas put on ending that inventory if the 95 percent arrives. If it does not, the show-cause order is still the thing with teeth.
Nothing in the filing has been approved as a class settlement. Nothing has been paid. The first dollar, if the lock holds, does not move until 2027, and even then it cannot exceed $3 billion. Haas also noted the company previously settled about 95 percent of filed mesothelioma lawsuits and retained the talc liabilities when Kenvue separated in August 2023. The 95 percent figure is now the ovarian book's on-switch.
Erik Haas put $5.5 billion down. Ninety-five percent have to take it, or the $5.5 billion stays a line in an 8-K.
Until 95 percent of the remaining claims sign on, Johnson & Johnson has announced a number, not written a check. The first payment window is 2027. The participation lock is now. Haas is the name on the quote. $5.5 billion is the number that does not move unless the firms deliver the inventory.
The Executive Briefing is five questions. It shows you exactly where the gaps are.
Take the Executive Briefing →Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.